Revenues and profits obtained by PET pioneer CTI Molecular Imaging dropped as expected in the third quarter (SCAN 8/16/04). Net revenues were $91.8 million, a 7.5% decline from the same period last year. Net income was $2.7 million, or 6¢ per share on a
Revenues and profits obtained by PET pioneer CTI Molecular Imaging dropped as expected in the third quarter (SCAN 8/16/04). Net revenues were $91.8 million, a 7.5% decline from the same period last year. Net income was $2.7 million, or 6¢ per share on a fully diluted basis, compared with $7.5 million, or 16¢ per share on a fully diluted basis, from the prior fiscal year's third quarter.
During the quarter, CTI sold 33 scanners and booked orders for an additional 42. The company expects the lull in demand to continue until the market absorbs the sharp increase in installed base that has occurred over the past two years.
Large Study Affirms Safety of Ultrasound Enhancing Agents for Echocardiography
May 16th 2025Those receiving ultrasound enhancing agents (UEAs) for transthoracic or stress echocardiography had lower odds of all-cause death in comparison to patients who did not have UEAs, according to a nationwide study involving 11.4 million patients.
BrightHeart Garners Third FDA Clearance for AI-Powered Assessments of Fetal Heart Ultrasound
May 14th 2025The latest FDA 510(k) clearance is for B-Right Views, an AI-enabled device, which provides automated detection of required views necessary for second- and third-trimester fetal heart ultrasound exams.